HIV pharmacotherapy
Authors:
- Nathan TrustmanNTNathan Trustman
- April YalongAYApril Yalong
- 1 February 2016
- journal article
- review article
- Published by Wolters Kluwer Health in JAAPA
- Vol. 29 (2) , 36-40
Abstract
Integrase strand transfer inhibitors (INSTIs) are a class of antiretroviral agents used to treat HIV. These drugs--raltegravir, elvitegravir, and dolutegravir--are preferred options for treatment-naïve patients when used in combination with two nucleoside reverse transcriptase inhibitors. Based on clinical trials, INSTIs have been proven to be effective with minimal safety concerns. This article reviews the pharmacologic profile, role in therapy, and safety and efficacy of each agent.Keywords
This publication has 10 references indexed in Scilit:
- Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING studyThe Lancet, 2013
- Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 studyThe Lancet, 2013
- Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeksThe Lancet, 2012
- HIV DNA IntegrationCold Spring Harbor Perspectives in Medicine, 2012
- Long-term Treatment With Raltegravir or Efavirenz Combined With Tenofovir/Emtricitabine for Treatment-Naive Human Immunodeficiency Virus-1–Infected Patients: 156-Week Results From STARTMRKClinical Infectious Diseases, 2011
- A randomized cross-over study to compare raltegravir and efavirenz (SWITCH-ER study)AIDS, 2011
- Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infectionAIDS, 2011
- A case of rhabdomiolysis associated with raltegravir useAIDS, 2010
- Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trialThe Lancet, 2009
- Severe rhabdomyolysis associated with raltegravir useAIDS, 2008